Carrie Smith Cox, President of Schering-Plough, dumped 900,000 shares of SGP stock last year worth $28 million, (not $14 million as we initially reported) shortly before prominent cardiologists and later Forbes and the New York Times started questioning the two-year delay in getting the results of the ENHANCE study.
The questions about the delayed trial data also resulted in a Congressional inquiry.
SGP stock has dropped to $24.00, a 14% decrease in less than two days, since the data was released, which means Carrie Cox's received about $5.6 million more when she sold than she would have made selling right now.
Comments